Purpose:To assess clinical results of the 9 mW/5.4 J/cm^(2) accelerated crosslinking(ACXL)in the treatment of progressive keratoconus(KC)over a span of 5 years.Methods:The prospective open non-randomized interventiona...Purpose:To assess clinical results of the 9 mW/5.4 J/cm^(2) accelerated crosslinking(ACXL)in the treatment of progressive keratoconus(KC)over a span of 5 years.Methods:The prospective open non-randomized interventional study(Siena Eye-Cross Study 2)included 156 eyes of 112 patients with early progressive KC undergoing the Epi-Off 9 mW/5.4 J/cm^(2) ACXL at the Siena Crosslinking Centre,Italy.The mean age was 18.05±5.6 years.The 20-min treatments were performed using the New KXL I(Avedro,Waltham,USA),10 min of 0.1%HPMC Riboflavin soaking(VibeX Rapid,Avedro,Waltham,USA)and 10 min of continuous-light UV-A irradiation.Uncorrected distance visual acuity(UDVA),corrected distance visual acuity(CDVA),Kmax,coma,minimum corneal thickness(MCT),surface asymmetry index(SAI),endothelial cell count(ECC)were measured,and corneal OCT performed.Results:UDVA and CDVA improved significantly at the 3rd(P=0.028),Δ+0.17 Snellen lines and 6th postoperative month,respectively(P<0.001),Δ+0.23 Snellen lines.Kmax improved at the 6th postoperative month(P=0.03),Δ−1.49 diopters from the baseline value.Also,coma aberration value improved significantly(P=0.004).A mild temporary haze was recorded in 14.77%of patients without affecting visual acuity and without persistent complications.Corneal OCT revealed a mean demarcation line depth at 332.6±33.6μm.Conclusion:The 5-year results of Epi-Off 9 mW/5.4 J/cm^(2) ACXL demonstrated statistically significant improvements in UCVA and CDVA,corneal curvature and corneal higher-order aberrations which confers a long-term stability for progressive ectasia.Based on the results of the Siena Eye-Cross Study 2,the 9 mW/5.4 J/cm^(2) ACXL is a candidate to be the natural evolution of Epi-Off CXL treatment for the management of early progressive corneal ectasia,and thus optimize clinic workflow.展开更多
文摘Purpose:To assess clinical results of the 9 mW/5.4 J/cm^(2) accelerated crosslinking(ACXL)in the treatment of progressive keratoconus(KC)over a span of 5 years.Methods:The prospective open non-randomized interventional study(Siena Eye-Cross Study 2)included 156 eyes of 112 patients with early progressive KC undergoing the Epi-Off 9 mW/5.4 J/cm^(2) ACXL at the Siena Crosslinking Centre,Italy.The mean age was 18.05±5.6 years.The 20-min treatments were performed using the New KXL I(Avedro,Waltham,USA),10 min of 0.1%HPMC Riboflavin soaking(VibeX Rapid,Avedro,Waltham,USA)and 10 min of continuous-light UV-A irradiation.Uncorrected distance visual acuity(UDVA),corrected distance visual acuity(CDVA),Kmax,coma,minimum corneal thickness(MCT),surface asymmetry index(SAI),endothelial cell count(ECC)were measured,and corneal OCT performed.Results:UDVA and CDVA improved significantly at the 3rd(P=0.028),Δ+0.17 Snellen lines and 6th postoperative month,respectively(P<0.001),Δ+0.23 Snellen lines.Kmax improved at the 6th postoperative month(P=0.03),Δ−1.49 diopters from the baseline value.Also,coma aberration value improved significantly(P=0.004).A mild temporary haze was recorded in 14.77%of patients without affecting visual acuity and without persistent complications.Corneal OCT revealed a mean demarcation line depth at 332.6±33.6μm.Conclusion:The 5-year results of Epi-Off 9 mW/5.4 J/cm^(2) ACXL demonstrated statistically significant improvements in UCVA and CDVA,corneal curvature and corneal higher-order aberrations which confers a long-term stability for progressive ectasia.Based on the results of the Siena Eye-Cross Study 2,the 9 mW/5.4 J/cm^(2) ACXL is a candidate to be the natural evolution of Epi-Off CXL treatment for the management of early progressive corneal ectasia,and thus optimize clinic workflow.
